RCM
ESPR

RA Capital Management’s Esperion Therapeutics ESPR Stock Holding History

RA Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-731,531
Closed -$33.9M – 29
2017
Q2 		$33.9M Buy
731,531
+26,830
+4% +$987K 3.89% 8
2017
Q1 		$24.9M Buy
+704,701
New +$16.1M 3.05% 10

Other funds holding ESPR

MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

RA Capital Management's ESPR Position: Q3 2017 in Review

RA Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2017, closing a stake of 731,531 shares — an estimated $33.9M sold.

RA Capital Management first reported a position in ESPR in Q1 2017 and held it in 2 quarters. The position peaked at $33.9M in Q2 2017. 150 funds tracked by Wall St. Rank hold ESPR as of Q3 2017.

  • RA Capital Management reported no remaining Esperion Therapeutics position as of Q3 2017 after selling out during the quarter.
  • RA Capital Management sold 731,531 Esperion Therapeutics shares in Q3 2017, an estimated $33.9M.
  • RA Capital Management first reported a position in Esperion Therapeutics in Q1 2017 and held it in 2 quarters.
  • RA Capital Management's Esperion Therapeutics position peaked at $33.9M in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2017.

Based on RA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.